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Cocaine addiction is accompanied by a decrease in striatal dopamine signaling, measured
as a decrease in dopamine D2 receptor binding as well as blunted dopamine release in the
striatum.These alterations in dopamine transmission have clinical relevance, and have been
shown to correlate with cocaine-seeking behavior and response to treatment for cocaine
dependence. However, the mechanisms contributing to the hypodopaminergic state in
cocaine addiction remain unknown. Here we review the positron emission tomography
(PET) imaging studies showing alterations in D2 receptor binding potential and dopamine
transmission in cocaine abusers and their significance in cocaine-seeking behavior. Based
on animal and human studies, we propose that the kappa receptor/dynorphin system,
because of its impact on dopamine transmission and upregulation following cocaine expo-
sure, could contribute to the hypodopaminergic state reported in cocaine addiction, and
could thus be a relevant target for treatment development.
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INTRODUCTION
Studies imaging the neurochemistry associated with cocaine
addiction in humans have largely focused on dopamine signaling
in the striatum. These studies show that pre-synaptic dopamine
release, in response to the administration of a stimulant, is reduced
in cocaine abusers compared to healthy controls. This has impor-
tant implications for this disorder, since the reduction in dopamine
release has been shown to correlate with increased cocaine-seeking
behavior. Importantly, the imaging studies were performed at
about 14 days abstinence, which has clinical relevance, since previ-
ous studies have shown that cocaine abusers who achieve 2 weeks
of abstinence have a better treatment response compared to those
who do not (Bisaga et al., 2010; Oliveto et al., 2012). Thus, a bet-
ter understanding of the mechanisms behind blunted dopamine
release would be expected to have implications for treatment
development. Among the possible mechanisms that are known to
regulate striatal dopamine release is dynorphin acting at the kappa
receptor. Kappa receptor activation in the striatum has been shown
to inhibit stimulant-induced dopamine release, in addition to stri-
atal dopamine levels and dopamine neurons activity (for review,
see Koob and Le Moal, 2008; Muschamp and Carlezon, 2013). Fur-
thermore, studies in humans and animals show that dynorphin is
significantly upregulated following chronic cocaine exposure, and
that this effect is long lasting (for review, see Koob and Le Moal,
2008; Muschamp and Carlezon, 2013), which could account for the
decrease in dopamine signaling seen after 2 weeks of abstinence in
the human imaging studies. Here, we review the data suggesting
that the cocaine-induced elevation in dynorphin may contribute
to the hypodopaminergic state observed in cocaine addiction.
PET IMAGING OF DOPAMINE TRANSMISSION IN COCAINE
ADDICTION
PRINCIPLES OF PET IMAGING
Positron emission tomography (PET) allows imaging of the neu-
rochemistry associated with drug and alcohol addiction in the
human brain. This imaging modality uses radionuclide-labeled
ligands that bind to a specific receptor, and the radioligands
used most frequently in addiction research label the dopamine
receptors. Radiotracers that label the dopamine type 2 family of
receptors (referred to as D2) can also be used to measure changes in
extracellular dopamine. This is performed by imaging with radio-
tracers that are sensitive to changes in extracellular dopamine,
and obtaining scans before and after the administration of a psy-
chostimulant (such as amphetamine or methylphenidate). These
stimulants increase extracellular dopamine levels, which results
in a reduction of dopamine receptors that are available to bind
to the radiotracer, shown in Figure 1. For reasons that are not
completely understood, this method can be used with most D2
receptor radiotracers but not with radiotracers that bind to the D1
receptor. Thus, imaging studies using the D2 receptor radiotracers
(such as [11C]raclopride or [18F]fallypride) can be used to mea-
sure changes in endogenous dopamine, whereas radiotracers that
label the D1 receptor (such as [11C]NNC112 or [11C]SCH23390)
cannot (Abi-Dargham et al., 1999; Chou et al., 1999; Laruelle, 2000;
Martinez and Narendran, 2010).
The main outcome measure in radioligand imaging studies is
receptor binding to the radiotracer, referred to as BPND, defined
as the ratio of specific to non-specific binding (Innis et al., 2007).
The change in extracellular dopamine resulting from stimulant
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FIGURE 1 | PET scans in a healthy control and cocaine-dependent
subject. The comparison of the top panels (pre- and post-amphetamine
administration) in the healthy control shows that radiotracer
([11C]raclopride) binding is reduced in the striatum following amphetamine.
The cocaine-dependent subject (bottom panel) has have lower D2 receptors
compared the control in the baseline condition. In addition, the cocaine
abuses has less radiotracer displacement (∆ BPND) following
amphetamine. Adapted from Trifilieff and Martinez “Cocaine: Mechanism
and Effects in the Brain” in “The Effects of Drug Abuse on the Human
Nervous System” M. Kuhar and B. Madras editors, 2012, publisher
Neuroscience-Net, LLC.
administration is measured by comparing baseline BPND (pre-
stimulant administration) and BPND following the stimulant.
This is used to derive the percent change in BPND, or ∆BPND,
defined as [(BPNDbaseline – BPNDchallenge)/BPNDbaseline].
Previous studies in non-human primates have shown that∆BPND
correlates linearly with changes in extracellular dopamine, mea-
sured with microdialysis (Breier et al., 1997; Endres et al., 1997;
Laruelle et al., 1997). Thus, ∆BPND provides an indirect mea-
sure of stimulant-induced pre-synaptic dopamine release, and can
be used to characterize the alterations in dopamine signaling that
occur in cocaine dependence.
PET IMAGING OF DOPAMINE RECEPTORS IN COCAINE ADDICTION
To date, six studies have been performed imaging the D2 recep-
tor in cocaine abusers, and these consistently show a decrease in
binding in the striatum compared to matched controls (Volkow
et al., 1990, 1993, 1997; Martinez et al., 2004, 2009a, 2011). The
decrease is about 15–20% and occurs in both the ventral and dor-
sal striatum. Importantly, animals with low D2 receptor levels in
the striatum, prior to drug exposure, display greater cocaine self-
administration (Morgan et al., 2002; Czoty et al., 2004; Nader et al.,
2006; Dalley et al., 2007). Imaging studies in humans show that low
striatal D2 receptor binding in cocaine abusers in the striatum cor-
relates with decreases in glucose metabolism in the orbito-frontal
cortex and cingulate gyrus, which process drive and affect, and
may lead to continued drug-taking behavior (Volkow et al., 1993,
1999). Several authors have proposed that changes in D2 receptor
binding in addiction could reflect behavioral vulnerability to drug
self-administration, such as lack of cognitive control or increased
impulsivity (Everitt et al., 2008; Dalley et al., 2011; Groman and
Jentsch, 2012).
One PET imaging study has measured D1 receptor binding
in cocaine abuse (Martinez et al., 2009b). This study showed no
difference in D1 receptor binding in cocaine abusers compared
to controls, which is consistent with a post-mortem study of stri-
atal D1 receptor mRNA (Meador-Woodruff et al., 1993). However,
the imaging study also showed that, within the cocaine-dependent
subjects, low D1 receptor binding in the ventral striatum was asso-
ciated with greater choices to self-administer cocaine. Thus, this
finding may represent a phenotype in which low D1 receptor bind-
ing in the limbic striatum is associated with a greater vulnerability
to the reinforcing effects of cocaine. This is in agreement with
pharmacologic studies in humans showing that stimulation of D1
receptors reduces, whereas blockade of the D1 receptor enhances,
the reinforcing effects of cocaine (Haney et al., 1999, 2001). Taken
together, these studies indicate that decreased signaling at the D1
receptor may be associated with more cocaine-taking behavior.
PET IMAGING DOPAMINE RELEASE IN COCAINE ABUSERS
Imaging studies measuring pre-synaptic dopamine release show
that cocaine dependence is associated with a reduction in respon-
siveness of the dopamine system to a stimulant challenge. For
example, in healthy human volunteers, the administration of a
psychostimulant produces a decrease in [11C]raclopride bind-
ing (∆BPND) of 15–20% (Volkow et al., 1994; Drevets et al.,
2001; Martinez et al., 2003; Munro et al., 2006), but in cocaine
abusers the decrease in [11C]raclopride binding is significantly
blunted (Volkow et al., 1997; Malison et al., 1999; Martinez et al.,
2007b, 2011). Thus, four studies have shown that cocaine depen-
dence is associated with reduced [11C]raclopride displacement
following stimulant administration compared to healthy controls,
which represents a reduction in pre-synaptic dopamine release.
PET imaging studies also show that cocaine abuse is associated
with both decreased [18F]DOPA uptake and striatal vesicular
monoamine transporter 2 binding, which provide measures of
pre-synaptic dopamine stores (Wu et al., 1997; Narendran et al.,
2012).
In addition to a reduction in stimulant-induced dopamine
release, PET imaging has also shown that dopamine levels in
the resting condition (without any stimulant administration) are
reduced in cocaine dependence. This is performed by imaging
the D2 receptors before and after acute depletion of endoge-
nous dopamine using alpha-methyl-para-tyrosine (AMPT). Thus,
imaging after AMPT administration results in an increase in
[11C]raclopride binding, as opposed to the decrease seen after
stimulant administration (Martinez et al., 2009a). AMPT admin-
istration resulted in an increase of 11.1± 4.4% in [11C]raclopride
binding in the striatum for healthy controls, but only 5.7± 5.9%
for cocaine-dependent volunteers (Martinez et al., 2009a), indi-
cating that basal dopamine levels are decreased in cocaine abuse.
Taken together, imaging studies in cocaine abuse consistently
show a reduction in striatal dopamine transmission, compared to
healthy controls, measured as decreased pre-synaptic dopamine
release (Volkow et al., 1997; Malison et al., 1999; Martinez et al.,
2007b, 2011) and reduced baseline levels of endogenous dopamine
(Martinez et al., 2009a). Similar findings have been shown in
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rodents (Parsons et al., 1991; Robertson et al., 1991; Rossetti et al.,
1992; Weiss et al., 1992; Gerrits et al., 2002) and non-human pri-
mates (Castner et al., 2000; Kirkland Henry et al., 2009). Thus,
cocaine dependence is associated with a hypodopaminergic state,
which correlates with behaviors that contribute to addiction and
relapse (Melis et al., 2005). Importantly, the PET scans showing
blunted dopamine release were obtained after about 2 weeks of
abstinence, to avoid the acute effect of cocaine on dopamine sig-
naling, and due to the clinical relevance of this time point. Previous
studies have shown that cocaine abusers who can achieve 2 weeks
of abstinence have a better treatment response compared to those
who do not (Bisaga et al., 2010; Oliveto et al., 2012).
SIGNIFICANCE OF THE HYPODOPAMINERGIC STATE IN
COCAINE ABUSE
The impact of dopamine transmission on addiction has been
demonstrated for decades, but its actual role in mediating the rein-
forcing effects of drugs of abuse remains under debate. Dopamine
does not appear to only signal “reward” (drug or natural rewards),
although dopamine neurons fire in response to the receipt of
a reward, and during the expectation of a reward. However,
dopamine signaling more likely mediates the reinforcing effects
of natural rewards and abused drugs, and makes the behavior
required to obtain the reward more likely to be repeated (Schultz,
2006; Berridge, 2007; Wise, 2008; Salamone and Correa, 2012).
However, the imaging studies in cocaine dependence consistently
show that pre-synaptic dopamine is reduced compared to controls,
indicating that this disorder is associated with a hypodopaminer-
gic state. This plays a crucial role in drug-seeking and taking, even
after prolonged drug-free periods (Melis et al., 2005).
The imaging studies in human cocaine abusers show that
blunted dopamine release correlates with an increase in cocaine
self-administration (Martinez et al., 2007b, 2011). These studies
showed that low dopamine release in cocaine abusers, measured
as ∆BPND, was associated with the decision to take cocaine in
the presence of competing non-drug reinforcers. The inability of
the cocaine-dependent subjects with low dopamine release to alter
their behavior can be viewed as an inability to respond to alter-
native sources of reward. This is consistent with the theory that
decreased dopamine function in addiction results in a decreased
interest to non-drug-related stimuli and increased susceptibility
to the drug of choice (Melis et al., 2005).
These studies raise the question regarding the mechanism
behind this decrease in pre-synaptic dopamine release. Previ-
ous studies in animals have shown that cocaine exposure results
in reduced burst firing of the dopamine neurons of the ven-
tral tegmental area (Brodie and Dunwiddie, 1990; Lacey et al.,
1990; Ackerman and White, 1992; Gao et al., 1998). Decreases
in extracellular dopamine levels in the nucleus accumbens have
also been reported following cocaine withdrawal (Parsons et al.,
1991; Robertson et al., 1991; Rossetti et al., 1992; Weiss et al.,
1992). Cocaine administration has also been shown to alter the
sensitivity of D2 autoreceptors of the midbrain (Gao et al., 1998;
Lee et al., 1999; Marinelli et al., 2003), which could reduce pre-
synaptic dopamine release. In addition to these functional changes
in dopamine signaling, animal studies have also shown that
cocaine exposure produces morphological changes in dopamine
neurons. These include alterations in dendritic spine density and
morphology and a reduction in the size of the dopamine neurons
of the ventral tegmental area (Melis et al., 2005).
Presently, it is unknown whether these changes occur in the
human brain. Human studies of the dopamine transporter (DAT),
which can serve as a marker for the integrity of the dopamine
neurons (Fusar-Poli and Meyer-Lindenberg, 2013), show that the
DAT is increased in post-mortem studies of cocaine abusers (Lit-
tle et al., 1993, 1999). However, imaging studies show that the
DAT is increased for a short time period following the cessation
of cocaine use, but soon return to control levels (Volkow et al.,
1996; Wang et al., 1997; Malison et al., 1998). But measuring DAT
binding alone is unlikely to reveal morphological alterations of
the dopamine neurons, and other means for investigating this
with imaging in humans are not yet available. With respect to
the dopamine receptors in the midbrain, one study in metham-
phetamine abusers and another in cocaine abusers showed that
D3 receptor binding is elevated in the substantia nigra/ventral
tegmental area (SN/VTA) compared to controls (Matuskey et al.,
2011; Boileau et al., 2012). The specific role of the D3 receptor
in the modulation of dopamine transmission and its function as
an autoreceptor are still highly debated (Sokoloff et al., 2006).
However, considering the possible implication of this receptor in
modulating dopamine synthesis and release (for review, Gross and
Drescher, 2012), an increase in D3 receptor levels in SN/VTA may
contribute to the hypodopaminergic state observed in addiction.
In addition to alterations in the dopamine neurons themselves,
it is possible that other neurotransmitter systems may be regu-
lating the dopamine system. Candidates include the glutamater-
gic, GABAergic, serotoninergic, or noradrenergic afferents to the
dopamine and striatal neurons, which have been reviewed previ-
ously (Melis et al., 2005; Gerfen and Surmeier,2011). In this review,
we focus on the kappa/dynorphin system as a potential modulator
of dopamine release in cocaine abuse for the following reasons:
(1) among the neurotransmitters that modulate dopamine trans-
mission, evidence from human and animal studies show that
cocaine exposure significantly upregulates kappa/dynorphin sig-
naling (for review, see Wee and Koob, 2010; Muschamp and
Carlezon, 2013); (2) in the striatum, dynorphin signaling strongly
regulates dopamine signaling and animal studies show that acti-
vation of the kappa system reduces pre-synaptic dopamine release
(Koob and Le Moal, 2008; Muschamp and Carlezon, 2013). Thus,
elevated striatal dynorphin activity at the kappa receptor could be
a compensatory adaptation that inhibits psychostimulant-induced
dopamine release (Koob and Le Moal, 2008; Muschamp and
Carlezon, 2013).
DYNORPHIN AND KAPPA RECEPTORS
KAPPA RECEPTOR/DYNORPHIN SIGNALING
Dynorphin (DYN) is the class of peptides cleaved from prodynor-
phin, which include dynorphin A and B (and others) which have
a high affinity for the kappa receptor (KOR) (Chen et al., 2007).
Currently, only one KOR subtype (type 1) has been cloned, and
while types 2 and 3 have been hypothesized, they have yet to be
fully characterized (Shippenberg et al., 2007). KOR selective ago-
nists and antagonists have been developed in recent years, allowing
investigation into the neurochemical and behavioral effects of the
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DYN/KOR system. The KOR agonists include the arylacetamides
U69593 and U50488, and salvinorin A, a naturally occurring alka-
loid found in the plant Salvia divinorum (Von Voigtlander and
Lewis, 1982; Lahti et al., 1985; Roth et al., 2002). The selec-
tive KOR antagonists include nor-binaltorphimine (nor-BNI),
5′-guanidinonaltrindole (GNTI), and JDTic (Endoh et al., 1992;
Jones and Portoghese, 2000; Carroll et al., 2004). Activation of
the KOR is aversive in both humans and animals, and KOR ago-
nists are not self-administered by animals (Mucha and Herz, 1985;
Tang and Collins, 1985; Pfeiffer et al., 1986; Bals-Kubik et al., 1993;
Walsh et al., 2001; Wadenberg, 2003), although the same cannot
be said of some humans.
KOR signaling is complex and agonists have been shown to
activate, inhibit and/or have no effect on downstream signal-
ing (i.e., cAMP, IP3/DAG, and Ca2+) depending on experimental
conditions (Tejeda et al., 2012). It is likely that KOR agonists dis-
play inverted U -shape effects, because of KOR ability to recruit
both inhibitory Gβγ, Gαi, Gαo, Gαz, and Gα16, and stimulatory,
Gαs, G-proteins (Law et al., 2000; Tejeda et al., 2012). Nanomo-
lar ligand concentrations result in the recruitment of inhibitory
G-proteins and a decrease in membrane excitability as well as
transmitter release via stimulation of K+-channel activity (Grudt
and Williams, 1993) and inhibition of Ca2+-channel and pre-
synaptic release machinery activity (Gross et al., 1990; Iremonger
and Bains, 2009). In contrast, sub-nanomolar ligand concentra-
tions may result in coupling of KOR to Gαs and produce opposite
effects (Crain and Shen, 1996; Tejeda et al., 2012). It should be
noted that KOR activity can modulate D2 autoreceptor-dependent
decrease in dopamine release by signaling interaction (Jackisch
et al., 1994; Acri et al., 2001; Fuentealba et al., 2006).
KAPPA RECEPTOR/DYNORPHIN IN DIRECT AND INDIRECT PATHWAYS
OF THE STRIATUM
The medium spiny neurons (MSNs) can be categorized into at least
two subgroups according to their projections sites and the pro-
teins they express (Gerfen, 2000; Gerfen and Surmeier, 2011). The
“direct” or striatonigral pathway made up of MSNs that project
monosynaptically to the medial globus pallidus and back to the
dopamine neuron cell bodies of the substantia nigra. MSNs from
the direct pathway express the dopaminergic D1 receptor, M4 mus-
carinic acetylcholine receptor, substance P, and dynorphin. The
indirect striatopallidal pathway is composed of MSNs that project
to the lateral globus pallidus, which reach the substantia nigra
through synaptic relays through the lateral globus pallidus and
subthalamic nucleus. These MSNs express the dopaminergic D2
receptor, adenosine receptors and enkephalin. It should be noted
that the segregation of these two populations of MSNs has been
established in the dorsal striatum, but that several studies show
that a subpopulation of MSNs in the NAc seem to co-express D1
and D2 receptors (George and O’Dowd, 2007; Valjent et al., 2009).
Dopamine can activate or inhibit cyclic AMP-dependent signaling
through D1 receptor and D2 receptor respectively, as we will review
below. Therefore, dopamine is likely to have differential effects on
D1- and D2-expressing MSNs and recent data suggest that, cocaine
administration activate signaling pathways in D1-expressing, but
actively inhibits them in D2-expressing MSNs (McClung et al.,
2004; Bateup et al., 2010), which could account for the imbalance
between direct and indirect pathways in addiction (Lobo et al.,
2010; Pascoli et al., 2012).
D1 receptors recruit adenylyl cyclase through activation of the
stimulatory Gαs protein and consequently stimulate the produc-
tion of adenosine 3′, 5′-monophosphate (cAMP) which leads to
the activation of protein kinase A (PKA)-dependent signaling
pathways. In contrast, D2 receptor inhibits adenylyl cyclase and
cAMP/PKA pathways by recruiting inhibitory Gαi. Accordingly,
cocaine activates PKA signaling pathway mainly through acti-
vation of D1 receptor and manipulation of this pathway alters
behavioral responses to cocaine (Girault, 2012). One of the down-
stream targets of PKA is the transcription factor CREB. Interest-
ingly, whereas overexpression of CREB in the nucleus accumbens
reduces the rewarding properties of cocaine, overexpression of a
dominant-negative form enhances it (Carlezon et al., 1998; Wal-
ters and Blendy, 2001; McClung and Nestler, 2008) suggesting
that activation of CREB could counteract the postsynaptic effects
of cocaine and therefore decrease behavioral response to cocaine.
One of the downstream genes regulated by CREB in the nucleus
accumbens encodes preprodynorphin, the precursor gene prod-
uct of dynorphin (McClung and Nestler, 2008). Activation of the
kappa receptor decreases cocaine-induced dopamine release (for
review, see Wee and Koob, 2010; Muschamp and Carlezon, 2013).
Accordingly, stimulation of the D1 receptor elevates dynorphin
expression, which can be blocked with receptor antagonists (Liu
and Graybiel, 1998). Thus, it has been proposed that activation of
the D1/PKA/CREB pathway could be counteracting the effects of
cocaine through synthesis and release of dynorphin (for review,
see Wee and Koob, 2010; Muschamp and Carlezon, 2013), shown
in Figure 2.
KAPPA RECEPTOR/DYNORPHIN AND DOPAMINE SIGNALING
The DYN/KOR receptor system has been shown to play a sig-
nificant role in regulating striatal dopamine transmission. DYN
immunoreactive axon terminals originating from D1 receptor-
expressing MSNs are found in the caudate, putamen, and nucleus
accumbens (Hurd and Herkenham, 1995; Van Bockstaele et al.,
1995). The KOR is expressed both pre- and post-synaptically on
dopamine neurons, and the pre-synaptic KOR is apposed to DAT
on the dopamine axon terminals, indicating that this system closely
regulates the mesoaccumbal dopamine neurons (Svingos et al.,
2001).
A number of animal studies have shown that the administra-
tion of a KOR agonist reduces dopamine levels in the striatum and
dopamine neuron activity in the nucleus accumbens and ventral
tegmental area (Di Chiara and Imperato, 1988; Heijna et al., 1990,
1992; Donzanti et al., 1992; Spanagel et al., 1992; Maisonneuve
et al., 1994; Xi et al., 1998; Thompson et al., 2000; Margolis et al.,
2003; Zhang et al., 2004b). In fact, KOR activation reduces basal
dopamine levels as well as stimulant-induced dopamine release
(cocaine) (Spanagel et al., 1990; Maisonneuve et al., 1994; Carlezon
et al., 2006; Gehrke et al., 2008). Reverse dialysis into the nucleus
accumbens reduces extracellular dopamine (Donzanti et al., 1992;
Zhang et al., 2004a). Notably, this effect is seen when the KOR
agonist is administered into the striatum, whereas administration
into the VTA appears to be species dependent (Spanagel et al.,
1992; Chefer et al., 2005; Ford et al., 2006; Margolis et al., 2006).
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FIGURE 2 | Model by which the dynorphin/kappa system could
counteract cocaine-induced dopamine release. Cocaine
administration elevates dopamine levels. Binding of dopamine on the D1
receptor expressed by medium spiny neurons from the striatonigral
pathway (direct pathway) activates the cAMP/PKA/CREB pathway which
leads to dynorphin (DYN) synthesis. Binding of DYN on kappa receptors
(KOR) located on dopamine terminals exert an inhibitory effect on
dopamine release.
KOR activation has been shown to inhibit electrically evoked
[3H]dopamine release in the nucleus accumbens (Heijna et al.,
1992; Yokoo et al., 1992), which also shows that activation of this
receptor reduces striatal dopamine transmission. More recently,
Chefer et al. (2005) showed that the deletion of KOR is associated
with an enhancement of basal dopamine release. Alternatively,
KOR antagonists stimulate the release of dopamine in the stria-
tum (Maisonneuve et al., 1994; You et al., 1999; Beardsley et al.,
2005). Lastly, repeated KOR agonist administration reduces striatal
D2 receptor density (Izenwasser et al., 1998). These findings show
that DYN/KOR signaling exerts inhibitory control over dopamine
release and dopamine receptor signaling in the striatum (Brui-
jnzeel, 2009; Wee and Koob, 2010) and demonstrate that excessive
KOR activation significantly reduces striatal dopamine transmis-
sion, independent of the modality used to measure dopamine
transmission.
Notably, imaging studies show that, in addition to cocaine
dependence, addiction to other substances of abuse also results in
blunted pre-synaptic dopamine release, measured with PET. This
finding has also been reported in studies of alcohol, methamphet-
amine, opiate, and tobacco dependence (Martinez et al., 2007a,
2012; Busto et al., 2009; Wang et al., 2012). While some studies
have shown that the DYN/KOR system plays a role in these disor-
ders as well (for review, see Wee and Koob, 2010; Koob, 2013), the
effect of drug exposure on KOR and DYN is less clear and may even
be down-regulated in methamphetamine and opiate dependence
(Drakenberg et al., 2006; Frankel et al., 2007). Further studies are
needed to clarify the interaction between the DYN/KOR system
and dopamine signaling in these disorders.
KAPPA RECEPTOR/DYNORPHIN SYSTEM IN COCAINE ABUSE
Three post-mortem studies have been performed investigating
KOR binding in cocaine abuse. The first of these, by Hurd and
Herkenham (1993), showed a twofold increase in KOR bind-
ing in the caudate, but not the putamen or ventral striatum, in
cocaine-dependent subjects compared to control subjects. Mash
and Staley (1999) used in vitro autoradiography and ligand bind-
ing to map KOR in the brains of cocaine abusers and showed a
twofold increase in the anterior and ventral sectors of the cau-
date and putamen, and nucleus accumbens compared to controls.
Similar results were reported by Staley et al. (1997) who used
radiolabeling to measure the KOR and reported a significant
increase in KOR in the caudate, putamen, and nucleus accum-
bens in cocaine exposed compared to control brain tissue. These
studies demonstrate that cocaine abuse or dependence is associ-
ated with a significant upregulation of the KOR in the striatum.
However, to date, no human in vivo imaging studies of the KOR
have been published in cocaine abuse. While previous PET studies
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imaged the mu opioid receptor in cocaine dependence (Zubieta
et al., 1996; Gorelick et al., 2008), PET imaging of the KOR has
not been previously possible due to the lack of an appropriate
radiotracer. Therefore, correlations with clinical outcomes, such
as cocaine-seeking behavior could not be performed. In addition,
these post-mortem studies did not measure markers of dopamine
transmission (such as receptor density or dopamine levels), so that
it remains unknown whether the increase in KOR signaling coin-
cides with a reduction in dopamine signaling largely described in
PET imaging studies. Measuring both KOR binding and dopamine
transmission in the same individuals will require the development
of new radiotracers for KOR.
COCAINE ADMINISTRATION AND DYNORPHIN
A number of animal studies have shown that repeated cocaine
administration increases levels of DYN, prodynorphin mRNA,
and preprodynorphin mRNA. The initial studies measured pep-
tide levels and showed that chronic dosing of cocaine increased
striatal dynorphin levels by 40–100% (Sivam, 1989; Smiley et al.,
1990). Further studies measuring prodynorphin and preprodynor-
phin mRNA, instead of peptide levels, have replicated these find-
ings. Daunais et al. (Daunais et al., 1993, 1995; Daunais and
McGinty, 1995, 1996) showed that cocaine self-administration
increases preprodynorphin mRNA in the caudate/putamen by
more than 100%. Similar results have been reported in studies
by other groups as well, where the administration of cocaine has
been shown to increase preprodynorphin mRNA levels 50–100%
in the caudate/putamen of rats and mice (Yuferov et al., 2001;
Zhou et al., 2002; Jenab et al., 2003; Schlussman et al., 2003, 2005;
Zhang et al., 2013). Spangler et al. (1993, 1996) demonstrated that
cocaine increased prodynorphin mRNA in the caudate/putamen
by 40%, and that these levels remained elevated for days. Over-
all, the above studies in rodents consistently report that cocaine
administration increases DYN, prodynorphin, and preprodynor-
phin mRNA with levels ranging from about 40 to 100%. Previous
studies have shown that the levels of DYN peptide and pro-
dynorphin/preprodynorphin mRNAs correlate with each other,
suggesting that increases in mRNAs closely reflect increases in the
peptide itself (Li et al., 1988; Sivam, 1996).
These findings in rodents have been replicated in studies of
rhesus monkeys and humans. Fagergren et al. (2003) performed
a study in rhesus monkeys who self-administered cocaine and
showed that prodynorphin mRNA levels were increased in the
dorsolateral caudate (83%), central caudate (34%), and the dor-
sal putamen (194%). In humans, Hurd and Herkenham (1993)
first reported that cocaine abuse was associated with an increase
in preprodynorphin mRNA in the putamen and caudate in a post-
mortem study of cocaine abusing subjects compared to control
subjects. More recently, Frankel et al. (2008) measured DYN pep-
tide levels in a post-mortem study of cocaine abusers and controls
subjects, and reported a significant increase in DYN in the cau-
date and a trend toward a significant increase in the putamen
compared to control subjects. A very large increase was seen in
the ventral pallidum but no difference was seen in the thalamus,
frontal, temporal, parietal, and occipital cortices. Taken together,
these studies indicate that cocaine exposure increases striatal DYN
signaling at the kappa receptor in rodents, non-human primates,
and humans. Considering the effect of DYN on dopamine signal-
ing, it is likely that the sustained increase in DYN levels by cocaine
exposure participates to the hypodopaminergic state described in
cocaine abusers.
Theses findings in human and animal studies suggest that treat-
ments that target KOR signaling would modulate cocaine-seeking
behavior. However,animal studies exploring the effect of KOR ago-
nist or antagonist administration on cocaine self-administration
are mixed (for review, see Wee and Koob, 2010; Butelman et al.,
2012). Partly, this effect depends on the reinforcement schedule
used, doses of drug administered, and timing of the effect, since
changes in KOR/DYN have a slow onset (Wee et al., 2009; Knoll
et al., 2011). Moreover, the DYN/KOR system appears to play a
more significant role in mediating the aversive effects that occur
with cocaine exposure.
KAPPA RECEPTOR/DYNORPHIN AND STRESSED-INDUCED
COCAINE-SEEKING BEHAVIOR
Animal studies have investigated the relationship between KOR
activation and stress-induced cocaine-seeking behavior. DYN is
released in response to physical stress in the striatum, amygdala,
and hippocampus (Shirayama et al., 2004; Land et al., 2008), and
blockade of the KOR reduces the effects of stress on cocaine-
seeking behavior. McLaughlin et al. (2003) showed that swim
stress and social defeat stress both significantly enhance condi-
tioned place preference (CPP) for cocaine in mice. This effect was
blocked by KOR antagonist administration and was not seen in
prodynorphin knock-out mice (McLaughlin et al., 2003, 2006). In
addition, the administration of a KOR agonist prior to cocaine
conditioning was shown to be as effective as stress in potentiat-
ing subsequent cocaine-induced CPP (McLaughlin et al., 2006).
Beardsley et al. (2005) showed that lever pressing for cocaine
is reinstated in rodents following uncontrollable footshock, and
that this effect is blocked by the administration of JDTic, a KOR
antagonist. Along these same lines, Redila and Chavkin (2008)
showed that intermittent foot shock, forced swim, and KOR ago-
nist administration all reinstate cocaine CPP in mice. This effect
was blocked with pre-treatment with the KOR antagonist nor-
BNI, and did not occur in mice lacking either the KOR or pro-
dynorphin. Carey et al. (2007) also showed that pre-treatment
with a KOR antagonist blocked stress-induced reinstatement of
cocaine CPP.
These studies show that signaling at the KOR plays a significant
role in cocaine-seeking behavior following stress. Recent studies
have also shown that DYN signaling and corticotropin releasing
factor (CRF) function together to increase the negative reinforc-
ing effects of cocaine (Koob et al., 2004). Land et al. (2008) used
a phospho-selective antibody for the activated form of KOR and
showed that both physical stress and CRF administration resulted
in DYN-dependent activation of the KOR. Valdez et al. (2007)
showed that, in monkeys, cocaine-seeking behavior is reinstated by
the administration of a KOR agonist, and that this effect is blocked
by CRF antagonist administration. KOR agonists stimulate the
HPA axis in rodents and humans (Ur et al., 1997; Laorden et al.,
2000), and it has previously been reported that KOR activation
elicits CRF release (Nikolarakis et al., 1986; Song and Takemori,
1992) and vice-versa (Land et al., 2008).
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Studies in human cocaine abusers have also shown that stress
increases the risk of drug abuse and relapse (De La Garza et al.,
2009). The pharmacological or psychological activation of the
hypothalamic pituitary adrenal axis has been shown to increase
craving in addition to the probability of increased cocaine use
(Elman et al., 2003; Shoptaw et al., 2004; Elman and Lukas,
2005). Sinha and colleagues have shown that stress imagery
increases anxiety and craving for cocaine (Sinha et al., 1999,
2006; Fox et al., 2006). Importantly, this group has also shown
that stress-induced cocaine craving is associated with a shorter
time to relapse in cocaine-dependent subjects following dis-
charge from inpatient treatment (Sinha et al., 2006). To date,
the imaging studies in addiction have not focused on stress-
induced reinstatement of cocaine-seeking behavior, and future
research should focus on the role of dopamine and KOR signaling
and stress.
Thus, DYN/KOR signaling appears to play a crucial role in rein-
stating drug-seeking behavior by mediating the negative effects
associated with drug cessation and stress-induced drug taking
(Koob and Le Moal, 2008; Muschamp and Carlezon, 2013).
CONCLUSION
The data presented here suggest that blunted striatal dopamine
release measured with imaging in cocaine dependence may be
associated with an upregulation of DYN. Acting at the KOR of the
dopamine terminals, KOR activation would be expected to pro-
duce a decrease in striatal dopamine release. Post-mortem studies
in cocaine abusers and animal studies show that both KOR and
DYN are upregulated following chronic cocaine exposure, and
that this effect is long lasting (Spangler et al., 1993, 1996). In
addition, the imaging studies in cocaine abusers show that blunted
dopamine release is associated with an increased risk of relapse
while animal studies show that activation of the KOR increases
cocaine self-administration. However, studies have not been con-
ducted measuring KOR and striatal dopamine signaling in human
cocaine abusers concurrently. Thus, future studies imaging the
KOR in cocaine abusers and correlating their level directly with
dopamine transmission, and with relevant clinical outcomes, is
needed.
Chronic cocaine exposure induces CREB phosphorylation and
changes in gene expression, which increase expression of pro-
dynorphin mRNA in the nucleus accumbens in addition to other
factors. As described above, excessive DYN signaling results in a
decrease in extracellular dopamine release, which has been shown
in the imaging studies of human cocaine abusers. These find-
ings suggest that increasing signaling at the dopamine receptors
may be an appropriate treatment approach, but clinical studies
using dopamine agonists have not shown efficacy (Amato et al.,
2011). Thus, pharmacologic manipulations that increase endoge-
nous dopamine may be of use, particularly since imaging studies
show that intact dopamine signaling is predictive of a positive
treatment response. The data reviewed here suggest that KOR
antagonists would be expected to counteract the effects of DYN
upregulation and may restore pre-synaptic dopamine release. In
addition, KOR antagonists have very limited, if any, nervous system
side effects (Kreek et al., 2012) and block stress-induced cocaine
self-administration in animal studies. Together, these findings sug-
gest that KOR antagonists may provide an important avenue for
future treatment development for cocaine addiction (Muschamp
and Carlezon, 2013).
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